Finance

Lists
603233:SHA
Dashenlin Pharmaceutical Group Co Ltd
CNÂ¥18.15
+2.43%
(+0.43) 1D
Aug 28, 3:00:03 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603233...
Open
CNÂ¥17.73
High
CNÂ¥18.30
Low
CNÂ¥17.59
Mkt. cap
20.67B
Avg. vol.
9.16M
Volume
8.75M
Dividend
4.57%
Quarterly dividend
CNÂ¥0.21
Ex-dividend date
Jun 26, 2026
P/E ratio
15.22
52-wk high
CNÂ¥21.78
52-wk low
CNÂ¥14.39
EPS
CNÂ¥1.19
Shares outstanding
400.01M
No. of employees
41K
Open
CNÂ¥17.73
High
CNÂ¥18.30
Low
CNÂ¥17.59
Mkt. cap
20.67B
Avg. vol.
9.16M
Volume
8.75M
Dividend
4.57%
Quarterly dividend
CNÂ¥0.21
Ex-dividend date
Jun 26, 2026
P/E ratio
15.22
52-wk high
CNÂ¥21.78
52-wk low
CNÂ¥14.39
EPS
CNÂ¥1.19
Shares outstanding
400.01M
No. of employees
41K
About Dashenlin Pharmaceutical Group Co Ltd
CEO-
Employees41.1K
FoundedFeb 12, 1999
Headquarters-
SectorDrug
Websitedslyy.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
6.55B
7.43B
6.97B
7.02B
Cost of goods sold
4.28B
5.01B
4.46B
4.55B
Cost of revenue
4.28B
5.01B
4.46B
4.55B
Research and development expenses
16.38M
-4.51M
9.63M
8.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.77B
1.95B
1.75B
1.78B
Operating expense
1.81B
2.04B
1.78B
1.81B
Total operating expenses
6.09B
7.05B
6.24B
6.36B
Operating income
458.77M
384.54M
733.21M
657.19M
Other non operating income
-21.09M
-641.08K
-7.75M
-54.56M
EBT including unusual items
398.31M
327.29M
707.02M
616.46M
EBT excluding unusual items
406.90M
360.61M
707.78M
620.32M
Income tax expense
95.80M
128.00M
163.45M
158.22M
Effective tax rate
24.05%
39.11%
23.12%
25.67%
Other operating expenses
21.41M
73.22M
22.65M
25.66M
Net income
282.83M
154.25M
511.14M
415.56M
Net profit margin
4.32%
2.07%
7.33%
5.92%
Earnings per share
-
0.13
0.45
-
Interest and investment income
15.03M
17.56M
17.38M
35.06M
Interest expense
-45.81M
-40.14M
-35.06M
-17.38M
Net interest expenses
-30.78M
-22.59M
-17.69M
17.69M
Depreciation and amortization charges
-
-
-
-
EBITDA
854.65M
451.17M
799.84M
735.62M
Gain or loss from assets sale
482.86K
-14.70M
-
-5.03M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps